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NFκB/p65 is a transcription factor that can protect or contribute to cell death. Here we show that knockdown of p65 by IκBSR or p65 siRNA
decreased the cytotoxic effect of DOX on HCT116 (p53+/+) cells, correlating with increased induction of p21. In previous work, we demonstrated
that p21 suppressed cell death via its CDK-inhibitory activity. Thus, we propose that the p65 activity is required for p53-dependent cell death
through limitation of p53-induced p21 expression. In HCT116 (p53−/−) cells, downregulation of p65 expression enhanced the cytotoxic effect of
DOX, due to decreased p21 expression levels. We present evidence that in p53-null tumor cells treated with DOX, p65 was involved in induction
of p21 expression by directly binding to the p21 promoter. Our data suggested that both p53 and p65 limited each other's ability to stimulate p21
induction and this mutual repression mechanism was consistent with a model in which both factors were competing for limiting pool of p300/CBP
coactivator protein complexes. These findings indicate an association between p21 expression and resistance to cell death through p65, a novel
regulatory mechanism in which p21 bridges a transcriptional crosstalk between p53 and p65.
© 2008 Elsevier B.V. All rights reserved.Keywords: p21; NFκB/p65; p53; CBP/p300; Cell death1. Introduction
In response to DNA damage induced by cytotoxic agents, the
tumor suppressor p53 accumulates and functions as a sequence-
specific DNA-binding protein, which positively regulates ex-
pression of several genes, including p21 (waf1/cip1/sdl1) [1].
P21 is an important cellular checkpoint protein for G1 and G2
arrest. Recently, contribution of p21 to suppression of DNA
damage agents induced cell death has been widely accepted [2–
7].
Nuclear factor-κB (NFκB) is a transcriptional factor involved
in the response to various stimuli and plays a central role in
inflammatory reactions. NFκB generally exists as an inactive
dimer sequestered in the cytoplasm by an inhibitor protein
termed IκB. Activation of NFκB involves phosphorylation of
IκB on two critical serine residues at codon 32 and 36. Once⁎ Corresponding author. Tel.: +86 21 65984636; fax: +86 21 65983793.
E-mail address: yanjunlu@hotmail.com (Y. Lu).
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doi:10.1016/j.bbamcr.2008.01.008phosphorylated, IκB is subjected to ubquitination at two lysine
residues and subsequent degradation by the 26S proteasome.
Unmasking IκB allows NFκB/p65 to translocate into the nuc-
leus, where it binds to the target genes, and promotes trans-
cription [8].
It is widely accepted that activation of NFκB may function to
protect cells from apoptosis in response to TNF-α treatment.
NFκB can also be implicated in cell cycle arrest. It has been
reported that a novel potential NFκB binding site is at position
−2008 of the p21 promoter and the binding of NFκB/p65 protein
to this κB site results in transactivation of p21 promoter by p65
[9].
In this study, we used HCT116 (p53+/+) cells and their
matched HCT116 (p53−/−) cells in which the p53 gene has been
deleted by homologous recombination. We showed that the
reduction of p65 remarkably decreased the cytotoxic effect of
Doxorubicin (DOX) onHCT116 (p53+/+) cells, correlating with
the increasing of induction for p21 level by p53 after transfection
with IκBSR (IκB α super-repressor) or p65 small interfering
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p65 enhanced the cytotoxic effect of DOX treatment due to the
decrease of p21 level. We also documented that in the absence of
p53, p65 was able to directly bind to the p21 promoter by
Chromatin Immunoprecipitation (ChIP). Our data suggested that
both p53 and p65 inhibited each other's ability to stimulate p21
expression and this mutual repression mechanism is consistent
with a model in which both factors are competing for limiting
pool of p300/CBP coactivator protein complexes. Thus we
presented evidence that p21 may be involved in transcriptional
cross talk between p53 and p65.
2. Materials and methods
2.1. Cells and transfection
Human colorectal cancer cell lines HCT116 (p53+/+) and HCT116 (p53−/−)
were generous gifts of Dr. B. Vogelstein. Cells were cultured in DMEMmedium
supplemented with 10% FBS (Hyclone, logan, UT). The plasmid expressing the
IκBSR was provided by Dr.Yamagishi (Kyoto University, Japan). IκBSR
containing the mutations at Ser32, Ser36 phosphorylation residues which cannot
be phosphorylated. P65 small interfering RNA (psiRNA-p65), was constructed
according to the procedure of psiRNA-hH1zeo kit (Invivogen, San Diego,
USA). Sense and antisense RNA oligonucleotides, 5′-CAAAAAAAGGT-
CATGGACGGTCTATCTCTTGAATAGACCGTCCATGACCTTT-3′ and 5′-
TCCCAAAGGTCATGGACGGTCTATTCAAGAGATAGACCGTCCAT-
GACCTTTT-3′, which contained the loop sequence were synthesized by
Sangon Ltd. (Shanghai, China). The plasmids of pRc/RSV-mCBP-HA and pRc/
RSV-p300 were kindly provided by Dr. Goodman (Oregon Health & Science
University, US). HCT116 cells were transiently transfected with expression
constructs for IκBSR, psiRNA-p65, pRc/RSV-mCBP-HA or pRc/RSV-p300,
using GeneJammer transfection reagents (Stratagene, La Jolla, CA).
2.2. Measurement of cell death
Cells were seeded into 96-well microtiter plates and transiently transfected
12 h with expression constructs for IκBSR, psiRNA-p65, pRc/RSV-mCBP-HA
or pRc/RSV-p300, followed by DOX treatment (2 μg/ml) for 24 h. Then 10 μl of
the CCK-8 solution was added to each well of the plates and then incubated for
2 h in the incubator (37 °C and 5% CO2). Cytotoxicity assay could be used with
the CCK-8 solution according to the procedure of Cell Counting Kit-8 (Dojindo
Laboratories, Tokyo, Japan). The absorbency was measured at 450 nm using a
microplate reader (BioTeK).
2.3. Western blotting and immunoprecipitation
The nuclear and cytoplasmic extract from the cells were prepared by
the Nuclear Extract Kit (Active Motif, Carlsbad, CA). The protein content of
the cell lysate was determined by using the Bradford calorimetric assay method
(Bio-Rad, Richmond, CA). The 40 μg aliquot of cytoplasmic or nuclear lysate
were resolved by 12% polyacrylamide-sodium lauryl sulfate gel electrophoresis
and transferred to a Hybond-C Super membrane (Amersham, Buckinghamshire,
UK). P65 and p21 were detected with an antibody against p65 (Upstate, U.S.A.)
and an antibody against p21 (Santa Cruz Biotechnology, CA), respectively.
Then the blot was incubated with a secondary antibody, IRDye 800 conjuga-
ted affinity purified anti-mouse or anti-rabbit IgG (Rockland Immunochemi-
cals, Inc., Gilbertsville, PA) and detected with Odyssey Infrared Imaging System
(LI-COR Bioscienceces, Nebraska, USA). For immunoprecipitation, a 500 μg
aliquot of cell lysate was incubated for 1 h at 4 °C with the anti-CBP antibody
(Santa Cruz Biotechnology, CA) or anti-p300 antibody (Santa Cruz Biotech-
nology, CA). Immune complexes were captured by incubation with 80 μl protein
G-plus-agarose (Santa Cruz Biotechnology, Santa Cruz, CA) for 10 h, then
washed several times with NP-40 buffer and lysed with loading buffer to do
Western blotting analysis. P65 was detected with an antibody against p65
(Upstate, U.S.A.).2.4. Cell growth analysis
Cells were washed twice with PBS, trypsinized and resuspended in PBS
containing 0.1% Triton X-100 and RNase (1 mg/ml) (Sigma, St Louis, MO). The
cell suspension was incubated at 37 °C for 30 min. Propidium iodide (Molecular
Probes, Inc. Eugene, OR) was added at a final concentration of 50 μg/ml and the
cell suspension was kept at 4 °C for 1 h. The cells were filtered and the cell cycle
was analysed by flow cytometry with the FACScan system (Becton Dickinson,
Franklin Lakes, NJ).
2.5. ChIP
HCT116 cells (5×108) were treated with or without DOX (2 μg/ml) for 24 h.
According to Chromatin Immunoprecipitation (ChIP) Assay Kit (Upstate), for-
maldehyde was added at 1% to the culture media and cells were incubated at room
temperature for 10 min with mild shaking. Protein-DNA complexes were
immunoprecipitated using the p65 antibody (Upstate) or mouse IgG control. DNAs
were purified and used for PCR with primers specific for the p21 gene promoter
region encompassing p65 binding sites. The primers of p21 were: 5′-TATTTGG-
GACTCCCCAGTCTCT-3′ and 5′-GGCTCTCTGCTTGTCATCCTTT-3′. The
primers of GAPDH were: 5′-TACTAGCGGTTTTACGGGCG-3′ and 5′-TCGAA-
CAGGAGGAGCAGAGAGCGA-3′.
2.6. Electrophoretic mobility shift assays
A 30 μl of annealing mixture containing 2 μl of each κB site oligonucleotide
(sense: 5′-AGT TGAGGGGAC TTT CCCAGGC-3′; antisense: 5′-GCC TGG
GAA AGT CCC CTC AAC T-3′) in 0.5 M NaCl was incubated 2 min at 80 °C
then stopped the heating and maintained in water bath until 35 °C. The above
8 μl of solution, 2 μl of 10× labeling Buffer and 2 μl IR Dye label solution
(IRDye™ 800 labeling kit, Odyssey, U.S.A.) were mixed, and the reaction
proceeded for 5 min at 70 °C.
The cells were washed with ice-cold PBS, and then collected. The nuclear
extracts were prepared by the Nuclear Extract Kit (Active Motif, Carlsbad, CA),
and 5 μg aliquots of the extracts were preincubated with 1.5 μl of above labeled
oligonucleotide on ice for 30 min. The complexes were resolved on a 5%
polyacrylamide gel. The gel was scanned by Odyssey infrared imaging system
(LI-COR Biosciences).
2.7. Northern blot analysis
Northern blotting was performed using total RNA following the protocol
provided with the Odyssey Infrared Imaging System (LI-COR Biosciences). Briefly,
5 μg total RNA per lane isolated from cells using TRIzol reagent (Invitrogen) were
electrophoresed and transferred onto Biodyne® B Nylon Membrane (Pall) using
the NorthernMax Kit (Ambion). RNA was cross-linked to the membrane the blot
was pre-hybridized at 42 °C with ULTRAhyb™-Oligo Buffer (Ambion). Blot was
hybridized overnight at 42 °Cwith biotinylated probeswhich had been denatured and
thenwashedwith NorthernMaxLow andHigh StringencyWashes. Blot was blocked
for 30 min with Odyssey® Blocking Buffer plus 1% SDS and then incubated for
30 min with Streptavidin IRDye 800 CW conjugate in blocking buffer plus 1% SDS
(LI-COR Biosciences). Blot was washed, then scanned by an Odyssey Infrared
Imaging System (LI-COR Biosciences).
HCT116 cell DNAwas used as a template for the PCR amplification in the
presence of biotin-16-dUTP (2:3 biotin-dUTP:TTP, Roche) to generate bio-
tinylated probes. The probe for β-actin mRNA is a PCR-amplified 0.5 kb coding
sequence, while the probe for p21 mRNA is 0.49 kb coding sequence.3. Results
3.1. Requirement of p65 for DOX-induced cell death in
p53-dependent way
P53 tumor suppressor is known to play an important role in
mediating DNA damage agents induced-cell death through a
Fig. 1. Role of down-regulation of p65 in DOX-induced cell death in HCT116
(p53+/+) and HCT116 (p53−/−) cells. Cells were transiently transfected with or
without IκBSR and psiRNA-p65 followed byDOX treatment (2 μg/ml) for 24 h.
(A) Cell survival was examined by CCK8 kit. Error bar indicates the standard
error of the mean of three independent experiments. (B)The nuclear and
cytoplasmic p65 protein were detected by Western blotting in HCT116 (p53+/+)
cells (above) and HCT116 (p53−/−) cells (bottom). β-actin and PCNAwere used
as controls. (C) Nuclear extracts from the cells were subjected to electrophoretic
mobility shift assay (EMSA) using IR Dye™ labeled κB oligonucleotide in
HCT116 (p53+/+) cells (above) and HCT116 (p53−/−) cells (bottom).
Fig. 2. Regulation of p21 expression by down-regulation of p65. HCT116 (p53+/+)
cells and HCT116 (p53−/−) cells were transiently transfected with or without IκBSR
and psiRNA-p65 followed by DOX treatment (2 μg/ml) for 24 h. (A)P21 protein
expression was detected by Western blotting in HCT116 (p53+/+) cells (above) and
HCT116 (p53−/−) cells (bottom). β-actin was used as control. (B) Northern blot of
total RNA from HCT116 (p53+/+) or HCT116 (p53−/−) cells. Hybridization with
biotinylated p21-specific probe (above) or biotinylatedβ-actin-specific probe
(bottom). (C) Cell cycle pattern of HCT116 (p53+/+) cells ( ) and transfected
with psiRNA-p65 (□) or HCT116 (p53−/−) cells ( ) and transfected with psiRNA-
p65 (■) followed by DOX treatment (2 μg/ml) for 24 h. Error bar indicates the
standard error of the mean of three independent experiments.
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treated HCT116 (p53+/+) cells and HCT116 (p53−/−) cells
with DOX for 24 h. As shown in Fig. 1A, DOX-induced cell
death was higher in p53+/+ cells than in p53−/− cells. This
result suggests a requirement of p53 for DOX-induced cell
death. P65 is involved in the regulation of cell death in several
systems. To examine the effect of p65 in this study, a vector was
generated to synthesize p65 small interfering RNA by the
human H1 polymerize III promoter. The p65 small interfering
RNA (psiRNA-p65) and the unphosphorylatable IκBαsuper-
repressor (IκBSR) were used to inhibit the activity of
endogenous NFκB/p65 in cells. The rate of cell survival was
shown in Fig. 1A. When the HCT116(p53+/+) cells were forced
to express IκBSR or p65 small interfering RNA, the percen-
tage of DOX-induced cell death were remarkably reduced as
compared to the control cells. In contrast, expression of IκBSR
or p65 small interfering RNA significantly sensitized to DOX-
induced cell death in HCT116(P53−/−) cells. The effects ofpsiRNA-p65 and IκBSR on cell death of HCT116(p53+/+) and
HCT116(P53−/−) cells were also shown in Fig. 1A. No effect
was seen after transfection of the empty vector.
The levels of nuclear activated and cytoplasmic inactivated
p65 were assessed by immunoblotting in HCT116 (P53+/+) and
HCT116 (P53−/−) cells. A clear reduction of nuclear activated
p65 was seen after expression of IκBSR or p65 small interfering
RNA(Fig. 1B). Electrophoretic mobility shift assays suggested
that over-expressing of IκBSR and psiRNA-p65 significantly
decreased the induction of NF-κB DNA-binding activity in
HCT116(p53+/+) and HCT116(p53−/−) cells treated with DOX
(Fig. 1C). These data led us to suggest that loss of NFκB/p65
activity specifically abrogated the p53-mediated cell death res-
ponse to DOX. On the other hand, these observation also
determined that in p53 null or defective tumors, targeting in
inhibition of NFκB/p65 activation was useful, leading to the
potency of DOX-treatment.
Fig. 3. Binding of P65 protein to the p21 promoter in HCT116 (p53−/−) cells.
(A) Cells were transiently transfected with or without pRc/RSV-mCBP-HA and
pRc/RSV-p300 followed by DOX treatment (2 μg/ml) for 24 h. The protein–
DNA complexes were cross-linked and immunoprecipitated by the indicated
antibodies. The precipitated DNA samples were analyzed by PCR using primers
of p21 and GAPDH. (B) Whole cell extract of HCT116 (p53+/+) cells (above)
and HCT116 (p53−/−) cells (bottom), treated as indicated was subjected to
immunoprecipitation with anti-300 antibody and then immunoblotted with anti-
p65 antibody.
Fig. 4. Effects of over-expression of CBP/p300 on HCT116 (p53+/+) cells treated
withDOX.Cells were transiently transfected with or without pRc/RSV-mCBP-HA
and pRc/RSV-p300 followed by DOX treatment (2 μg/ml) for 24 h. (A)Whole cell
extract was subjected to immunoprecipitation with anti-CBP antibody or anti-p300
antibody and then immunoblotted with anti-p65 antibody. (B) P21 expression was
determined by Western blotting analysis. β-actin was used as control. (C) Cell
deathwas examined byCCK8 kit. Error bar indicates the standard error of themean
of three independent experiments.
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In previous studies, we showed that DOX is a cell cycle-
dependent anti-tumor drug and p21 suppresses DOX-induced
cell death by arresting cells at G1 or G2 phase [5,6]. The
expression level of p21 increased in p53-dependent or p53-
independent pathway. To investigate the role of p21 in this
study, we assessed the expression levels of p21 protein and
mRNA in both HCT116 (p53+/+) and HCT116 (p53−/−) cells.
As shown in Fig. 2A, the p21 protein expression level in the cell
extract was elevated in HCT116 (p53+/+) cells after transfec-
tion with IκBSR or p65 small interfering RNA followed by
DOX treatment (2 μg/ml) for 24 h. Interestingly, under identical
conditions to HCT116 (p53−/−) cells, the p21 level was down
regulated, as compared to the control cells. Moreover, the
expression levels of p21 mRNA corresponded to their pro-
teins pattern in HCT116 (p53+/+) and HCT116 (p53−/−) cells
(Fig. 2B). To examine the change in the cell cycle pattern of
these cells after regulating of p21 expression by p65, the flow
cytometry was carried out (Fig. 2C). As expected, in HCT116
(p53+/+) cells a fraction of G1-phase cells was increased from
67 to 81%, indicating the cell cycle is arrested at G1-phase
due to increasing of p21 expression. On the other hand, in the
HCT116 (p53−/−) cells the fraction of G1-phase cells was
decreased from 61 to 35% by reducing of p21 expression.
These data led us to suggest that p65 limited p53-induced
p21 expression in p53+/+ cells and was involved in inducing
p21 expression in p53−/− cells after DOX treatment. In com-
bination with our previous data that over expression of p21
prevents cell death due to its ability to stop cell cycle, we could
suggest that p65 may be necessary for DOX-induced cell death
in p53-dependent way.
To further determine whether p65 was involved in induction
of p21 expression, we preformed the Chromatin Immunopre-
cipitation assay to examine the ability of p65 to bind to thep21 promoter. After cross-linking and immunoprecipitation
with anti-p65 antibody, PCR using a pair of primers to the
fragment that contains κB site at position −2008 of the p21
promoter showed a DNA band in HCT116 (p53−/−) cells but
not in HCT116 (p53+/+) cells with DOX treatment. Moreover,
the DNA band was found in HCT116 (p53+/+) cells after
transiently over-expressing transcriptional coactivator pro-
teins p300 and CREB-binding protein (CBP) (Fig. 3A above),
thereby suggesting that the competition between p53 and p65
for limiting quantities of endogenous transcriptional coactivator
protein CBP/p300. For negative control, we performed PCR
using a pair of primers to the fragment of GAPDH promoter,
showed no DNA band in the presence of p65 antibody (Fig. 3A
bottom).
To further prove that p53 competition with p65 for limiting
pool of CBP/p300 coactivator protein complexes, we performed
the coimmunoprecipitation with anti-p300 antibody and then
immunoblotted with anti-p65 antibody. We observed the DOX
treatment increased binding of p300 to p65 in HCT116 (p53−/−)
cells as compared to HCT116 (p53+/+) cells, which shown in the
Fig. 3B.
These data suggested that in tumor cells that are p53-null
or defective, NFκB/p65 was involved in induction of p21
expression after DOX treatment by directly binding to the
p21 promoter. It may need further to elucidate the association
between p21 expression and resistance to cell death by NFκB
activation.
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CBP/p300
These observations above suggested that both p53 and p65
inhibited each other's ability to stimulate their gene expression
and this mutual repression mechanism is consistent with a
model in which both factors are competing for limiting pool of
CBP/p300 coactivator protein complexes. This idea has been
reinforced by several reports [13–18]. Here, in an attempt to
understand how CBP/p300-dependent crosstalk between p65
and p53 is regulated in this study, we performed the immu-
noprecipitation with anti-CBP antibody or anti-p300 anti-
body and then immunoblotted with anti-p65 antibody. As
shown in Fig. 4A, after over expressing of CBP and p300
protein, the binding of CBP and p300 to p65 was increased
in HCT116 (p53+/+) cells with DOX treatment. In parallel with
these results, we also observed that p21 protein levels were
elevated (Fig. 4B). These data suggested that high level of
CBP or p300 proteins increased their binding to p65 and then
restored the p65 transcriptional activity of p21-induction in
HCT116 (p53+/+) cells. Next we examined the direct effect
of CBP/p300 over-expression on the HCT116 (p53+/+) cells
treated with DOX (2 μg/ml) for 24 h (Fig. 4C). As expected,
upon over-expression of CBP/p300, cell death rate decreased in
comparison to that in the cells transfected with a control vector.
It indicated that suppression of p53 transactivation through
induction of p21 by p65 might result from limiting quantities
of endogenous levels of this transcription factors CBP/p300. The
present data suggested the regulation of the transcriptional
decision-making mechanism that may be a key player in cellu-
lar processes such as cell death.
4. Discussion
In this study, we showed that the down-regulation of p65
remarkably decreased the cytotoxic effect of DOX on HCT116
(p53+/+) cells. That correlated with the increasing of induction
for p21 level by p53 after transfection with IκBSR or p65 small
interfering RNA. In contrast, on HCT116 (p53−/−) cells the
down-regulation of p65 enhanced the cytotoxic effect to DOX
treatment due to the decrease of p21 level. We documented that
in the absence of p53, p65 was able to directly bind to the p21
promoter. Our data suggested that both p53 and p65 inhibited
each other's ability to stimulate p21 induction and this mutual
repression mechanism is consistent with a model in which both
factors are competing for limiting pool of p300/CBP. Thus we
presented evidence that p21 may be involved in transcriptional
cross talk between p53 and p65.
In response to DOX, p21 is regulated transcriptionally by
p53. Our previous data suggested that expression of p21 im-
pedes DOX-induced cell death by inactivation of cyclin-
dependent kinase (CDK) activity, which in turn blocks the
cell cycle at the G1 and G2 phases [6]. The present findings here
reinforced this idea by showing p21's ability of abrogating
DOX-induced cell death correlated with its inhibition of cell
cycle progression after reducing p65 in p53+/+ cells (Fig. 1A
and Fig. 2).Recent studies have shown the existence of p21 induction in
a p53-independent pathway. Here we observed p21 induction in
NFκB/p65-dependent mechanism. Our data indicated that
DOX-induced NFκB/p65 complexes were able to bind the
p21 promoter to activate its transactivation in HCT116 (p53−/−)
cells but not HCT116 (p53+/+) cells (Fig. 3). It suggested the
competition between p53 and p65 in induction of p21 expres-
sion in response to DOX.
Many cellular stimuli result in the induction of both p53 and
NFκB/p65 [19–21]. The tumor suppressor p53 inhibits cell
growth through activation of cell-cycle arrest and apoptosis.
NFκB/p65 is a transcription factor that can protect or contri-
bute to apoptosis [22,23]. These observations suggest that a
regulatory mechanism must exist to integrate and coordinate
this critical cellular decision-making event. Webester's group
found that the transcriptional activities of p53 and p65 are
governed by their relative levels of expression: p65 inhibits p53-
dependent transactivation,while p53 expression can also suppress
p65 transcriptional activity [13]. Growing evidences show that
both p53 and p65 interact with the transcriptional coactivator
protein p300 and CBP. It is important to notice that reducing 50%
of the level of expression of both p300 and CBP in mice, which
result in profound developmental defects in mice, confirming that
these coactivator proteins are at limiting concentrations in vivo
[24,25]. In present study, we found that p53 transactivation of
inducing p21 was suppressed by p65, as evidenced by a clear
elevation of p21 level induced by p53 after knockdown of p65 by
IκBSR or p65 small interfering RNA (Fig. 2A). Moreover, DOX
treatment increased binding of p300 to p65 in HCT116 (p53−/−)
cells as compared to HCT116 (p53+/+) cells. Then p65 was able
to bind the p21 promoter to activate its transactivation in HCT116
(p53−/−) cells but not HCT116 (p53+/+) cells (Fig. 3). Over
expression of transcriptional coactivator proteins p300 and CBP
increased the binding to p65 and then restored p65 transcriptional
activity of inducing p21 in HCT116 (p53+/+) cells (Fig. 4).
Lately, Huang and coworkers clearly established a role of nuclear
IKKα can phosphorylate CBP thus to switch the binding from
p53 to p65 [26]. Thus, togetherwith other reports we could favor a
model in which p53 can also limit p65-mediated transactivation
and this mutual repression mechanism is due to their limiting
common coactivators of transcription.
It has been shown that loss of NFκB/p65 activity specifi-
cally abrogated the p53-mediated cell death response to DOX
(Fig. 1A and [27]). The present findings indicate that p65 limiting
p53-induced p21 expression by competition with endogenous
transcriptional coactivators CBP/p300 are at least in part respon-
sible for that the p65 activity was required for p53-induced cell
death.
It has been reported that NFκB/p65 can mediate to stop cell
cycle and to protect cell apoptosis [28–30]. Here we suggested that
in tumor cells that are p53-null, NFκB/p65 was involved in
induction of p21 expression by directly binding to the p21
promoter. Our previous data suggested that NFκB/p65-induced
anti-apoptotic gene expressions are higher in p53−/− cells than in
p53+/+ cells [31]. Thus, we could speculate that NFκB/p65 mostly
promotes to induce anti-apoptotic gene expressions without
competing with p53 in p53−/− cells.
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active in some diseases, such as ataxia telangiectasia, Hodgkin's
lymphoma and breast cancer [32,33]. It could speculate that
transactivation by p65 might contribute to p65 role in tumo-
rigensis. It is worth noting that in p53 null or defective tumors,
targeting in inhibition of NFκB/p65 activation may well be
useful, leading to the potentiality of chemotherapeutic drugs.
However, in tumors that retain wild-type p53, such targeting
may be counter productive, because it is likely to result in the
repression of p53-mediated tumor cell death.
In the present study, we observed that the p21 expression
level was a key player in the transcriptional cross talk between
p53 and NFκB/p65. The clear elevation of p21 expression after
reducing p65 may provide a good rationale for resistance to
DOX treatment in HCT116 (p53+/+) cells. In our previous work
reported that a combined treatment DOX-TNF-α is an effective
chemotherapeutic strategy for cancer due to that p21's negative
regulation on CDK2 is blocked by DOX-TNF-α treatment [34].
Thus, we propose that it may be important in the design of
therapeutic protocols that involve targeting of p21 to mediate
tumor's sensitivity to the drugs.
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